Zobrazeno 1 - 10
of 395
pro vyhledávání: '"Eva Ciruelos"'
Autor:
Fara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato, Olga Martínez-Sáez, Juan Miguel Cejalvo, Mireia Margelí, Pablo Tolosa, Francisco Javier Salvador-Bofill, Josefina Cruz, Blanca González-Farré, Esther Sanfeliu, Andreu Òdena, Violeta Serra, Francisco Pardo, Ana María Luna Barrera, Miriam Arumi, Juan Antonio Guerra, Guillermo Villacampa, Rodrigo Sánchez-Bayona, Eva Ciruelos, Martín Espinosa-Bravo, Yann Izarzugaza, Patricia Galván, Judith Matito, Sonia Pernas, Maria Vidal, Anu Santhanagopal, Dalila Sellami, Stephen Esker, Pang-Dian Fan, Fumitaka Suto, Ana Vivancos, Tomás Pascual, Aleix Prat, Mafalda Oliveira
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Patritumab deruxtecan (HER3-DXd) exhibits promising efficacy in breast cancer, with its activity not directly correlated to baseline ERBB3/HER3 levels. This research investigates the genetic factors affecting HER3-DXd’s response in women w
Externí odkaz:
https://doaj.org/article/7c7d4486147e4021ad5651e0e2b54a88
Autor:
Pierfranco Conte, Eva Ciruelos, Giuseppe Curigliano, Michelino De Laurentiis, Lucia Del Mastro, Alessandra Gennari, Antonio Llombart, Miguel Martìn, Francesca Poggio, Aleix Prat, Fabio Puglisi, Cristina Saura
Publikováno v:
Breast, Vol 76, Iss , Pp 103742- (2024)
Introduction: Advancements in monoclonal antibodies, tyrosine kinase inhibitors, and antibody drug conjugates (ADCs) have notably enhanced outcomes for metastatic HER2-positive breast cancer patients. Despite the expanding treatment options and clini
Externí odkaz:
https://doaj.org/article/3fd5c1f752464c7f896a88384ff626ee
Autor:
Tomás Pascual, Aranzazu Fernandez-Martinez, Yash Agrawal, Adam D. Pfefferle, Nuria Chic, Fara Brasó-Maristany, Blanca Gonzàlez-Farré, Laia Paré, Guillermo Villacampa, Cristina Saura, Cristina Hernando, Montserrat Muñoz, Patricia Galván, Xavier Gonzàlez-Farré, Mafalda Oliveira, Miguel Gil-Gil, Eva Ciruelos, Patricia Villagrasa, Joaquín Gavilá, Aleix Prat, Charles M. Perou
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-11 (2024)
Abstract In this study, we performed genomic analyses of cell cycle and tumor microenvironment changes during and after ribociclib and letrozole or chemotherapy in the CORALLEEN trial. 106 women with untreated PAM50-defined Luminal B early breast can
Externí odkaz:
https://doaj.org/article/3f189cf1ef8a4f74a950d11ff22079b9
Autor:
Antonio Llombart-Cussac, José Manuel Pérez-Garcia, Manuel Ruiz Borrego, Pablo Tolosa, Salvador Blanch, Adela Fernández-Ortega, Ander Urruticoechea, Isabel Blancas, Cristina Saura, Beatriz Rojas, Begoña Bermejo, José Ponce Lorenzo, María Gion, Patricia Cortez-Castedo, Elisenda Llabres, Elena Galve, Juan Fernando Cueva, Ana López, José Luis Alonso-Romero, Santiago González-Santiago, Eduardo Martínez de Dueñas, Eva Ciruelos, Griselda Martrat, Petra Gener, Daniel Alcalá-López, Miguel Sampayo-Cordero, Fernando Gómez-Peralta, Javier Cortés
Publikováno v:
EClinicalMedicine, Vol 71, Iss , Pp 102520- (2024)
Summary: Background: Hyperglycaemia is an early and frequent adverse event during alpelisib treatment. METALLICA aimed to evaluate prophylactic metformin to prevent or reduce hyperglycaemia occurrence in patients with HR+/HER2−/PIK3CA-mutated advan
Externí odkaz:
https://doaj.org/article/c5ba8bd9a6864624b463e00529accd71
Autor:
Santiago Terán, Manuel Alva, Pablo Tolosa, Macarena Rey-Cárdenas, Ainhoa Madariaga, Laura Lema, Yolanda Ruano, Luis Manso, Eva Ciruelos, Rodrigo Sánchez-Bayona
Publikováno v:
Breast, Vol 71, Iss , Pp 42-46 (2023)
Background: HER2-low has emerged as a new predictive biomarker in metastatic breast cancer. However, its prognostic value in early-stage carcinomas needs to be revisited. We aimed to evaluate the association of HER2-low carcinomas with PAM50 risk gro
Externí odkaz:
https://doaj.org/article/45206221d7664a38bf63504773e67ed3
Autor:
Nuria G. Martínez-Illescas, Silvia Leal, Patricia González, Osvaldo Graña-Castro, Juan José Muñoz-Oliveira, Alfonso Cortés-Peña, María Gómez-Gil, Zaira Vega, Verónica Neva, Andrea Romero, Miguel Quintela-Fandino, Eva Ciruelos, Consuelo Sanz, Sofía Aragón, Leisy Sotolongo, Sara Jiménez, Eduardo Caleiras, Francisca Mulero, Cristina Sánchez, Marcos Malumbres, María Salazar-Roa
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-21 (2023)
Abstract A hallmark of many malignant tumors is dedifferentiated (immature) cells bearing slight or no resemblance to the normal cells from which the cancer originated. Tumor dedifferentiated cells exhibit a higher capacity to survive to chemo and ra
Externí odkaz:
https://doaj.org/article/563051e71f9b4c11bb12717d56311f38
Autor:
Aleix Prat, Fara Brasó-Maristany, Olga Martínez-Sáez, Esther Sanfeliu, Youli Xia, Meritxell Bellet, Patricia Galván, Débora Martínez, Tomás Pascual, Mercedes Marín-Aguilera, Anna Rodríguez, Nuria Chic, Barbara Adamo, Laia Paré, Maria Vidal, Mireia Margelí, Ester Ballana, Marina Gómez-Rey, Mafalda Oliveira, Eudald Felip, Judit Matito, Rodrigo Sánchez-Bayona, Anna Suñol, Cristina Saura, Eva Ciruelos, Pablo Tolosa, Montserrat Muñoz, Blanca González-Farré, Patricia Villagrasa, Joel S. Parker, Charles M. Perou, Ana Vivancos
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-16 (2023)
Plasma ctDNA is a promising method to determine patient outcome in multiple cancer types. Here, the authors use shallow WGS to create machine learning signatures to identify tumor phenotypes and predict therapy response in patients with metastatic br
Externí odkaz:
https://doaj.org/article/3f12bbd8bddf4a1d9f66456aec50f23c
Autor:
Rubén Olivera-Salguero, Elia Seguí, Juan Miguel Cejalvo, Mafalda Oliveira, Pablo Tolosa, Maria Vidal, Marcos Malumbres, Joaquín Gavilá, Cristina Saura, Sonia Pernas, Rafael López, Mireia Margelí, Judith Balmaña, Montserrat Muñoz, Isabel Blancas, Valentina Boni, Eva Ciruelos, Elena Galve, Antonia Perelló, Rodrigo Sánchez-Bayona, Susana de la Cruz, Miguel de la Hoya, Patricia Galván, Esther Sanfeliu, Blanca Gonzalez-Farre, Valeria Sirenko, Aura Blanch-Torras, Jordi Canes, Helena Masanas, Rosa Olmos, Margarita Forns, Aleix Prat, Ana Casas, Tomás Pascual
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundMetastatic breast cancer (mBC) causes nearly all BC-related deaths. Next-generation sequencing (NGS) technologies allow for the application of personalized medicine using targeted therapies that could improve patients’ outcomes. However,
Externí odkaz:
https://doaj.org/article/824e6c3277784295a0300733bf18032a
Autor:
Belén Díaz‐Antón, Rodrigo Madurga, Blanca Zorita, Samantha Wasniewski, Andrea Moreno‐Arciniegas, Beatriz López‐Melgar, Natalia Ramírez Merino, Roberto Martín‐Asenjo, Patricia Barrio, Maximiliano German Amado Escañuela, Jorge Solís, Francisco Javier Parra Jiménez, Eva Ciruelos, José María Castellano, Leticia Fernández‐Friera
Publikováno v:
ESC Heart Failure, Vol 9, Iss 2, Pp 1127-1137 (2022)
Abstract Aims To evaluate echocardiographic and biomarker changes during chemotherapy, assess their ability to early detect and predict cardiotoxicity and to define the best time for their evaluation. Methods and results Seventy‐two women with brea
Externí odkaz:
https://doaj.org/article/0029eef9d0994ae1b0c0e348fa7da671
Autor:
Fara Brasó‐Maristany, Laia Paré, Nuria Chic, Olga Martínez‐Sáez, Tomás Pascual, Meritxell Mallafré‐Larrosa, Francesco Schettini, Blanca González‐Farré, Esther Sanfeliu, Débora Martínez, Patricia Galván, Esther Barnadas, Belinda Salinas, Pablo Tolosa, Eva Ciruelos, Esther Carcelero, Cecilia Guillén, Barbara Adamo, Reinaldo Moreno, Maria Vidal, Montserrat Muñoz, Aleix Prat
Publikováno v:
Molecular Oncology, Vol 16, Iss 1, Pp 69-87 (2022)
In advanced breast cancer, biomarker identification and patient selection using a metastatic tumor biopsy is becoming more necessary. However, the biology of metastasis according to the organ site is largely unknown. Here, we evaluated the expression
Externí odkaz:
https://doaj.org/article/ba667a7f8a964a6a8d8410bb45690ce0